Emerging findings in ethics of schizophrenia research

Current Opinion in Psychiatry

Volumn 18, Issue 2, 2005, Pages 111-119

  Dunn, Laura B ^a   Roberts, Laura Weiss ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Decision making capacity; Empirical studies; Ethical issues; Schizophrenia

Indexed keywords

EMPIRICISM; HUMAN; INFORMED CONSENT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL RESEARCH; PERCEPTION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 20444502498     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200503000-00003     Document Type: Review

References (122)

1. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 1994.
2. Freedman R. Schizophrenia. N Engl J Med 2003; 349:1738-1749.
3. Uhl GR, Grow RW. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 2004; 61:223-229.
4. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30:193-217.
5. Corrigan PW, Reinke RR, Landsberger SA, et al. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr Res 2003; 63:97-101.
6. Tandon R, Jibson MD. Pharmacologic treatment of schizophrenia: what the future holds. CNS Spectr 2000; 6:980-984.
7. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2004; 3 August (epub ahead of print).
8. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003; 122:69-87.
9. Callicott JH. An expanded role for functional neuroimaging in schizophrenia. Curr Opin Neurobiol 2003; 13:256-260.
10. Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161:780-796.
11. Mancama D, Arranz MJ, Kerwin RW. Pharmacogenomics of psychiatric drug treatment. Curr Opin Mol Ther 2003; 5:642-649.
12. Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 2001; 158:163-175.
13. Penn DL, Mueser KT, Tarrier N, et al. Supportive therapy for schizophrenia: possible mechanisms and implications for adjunctive psychosocial treatments. Schizophr Bull 2004; 30:101-112.
14. Twamley EW, Jeste DV, Bellack AS. A review of cognitive training in schizophrenia. Schizophr Bull 2003; 29:359-382.
15. Candilis PJ. Early intervention in schizophrenia: three frameworks for guiding ethical inquiry. Psychopharmacology 2003; 171:75-80.
16. Yung AR, Phillips U, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67:131-142.
17. McGlashan TH, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I: Study rationale and design. Schizophr Res 2003; 61:7-18. Describes the design of the PRIME study, in which patients at risk of developing psychosis were randomized to olanzapine or placebo. Touches upon some of the ethical considerations in prodromal schizophrenia studies.
18. Sevy S, Visweswaraiah H, Mentschel C, et al. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. J Clin Psychiatry 2004; 65:756-765.
19. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161:692-699.
20. National Institute of Mental Health. The numbers count: mental disorders in America, http://www.nimh.nih.gov/publicat/bnumbers.cfm. [Accessed 30 September 2004]
21. Roberts LW. The ethical basis of psychiatric research: conceptual issues and empirical findings. Compr Psychiatry 1998; 39:99-110.
22. Hilts PJ. Psychiatric researchers under fire. New York Times 1998; 19 May:B11, B14.
23. National Bioethics Advisory Commission. Research involving persons with mental disorders that may affect decision-making capacity. Report of the recommendations of the National Bioethics Advisory Commission. Rockville, MD: National Bioethics Advisory Commission; 1998.
24. Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997; 54:401-407.
25. Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry 2000; 47:707-716.
26. Roberts LW, Geppert CM, Brody JL. A framework for considering the ethical aspects of psychiatric research protocols. Compr Psychiatry 2001; 42: 351-363.
27. Roberts LW. Ethics and mental illness research. Psychiatr Clin North Am 2002; 25:525-545.
28. Rosenstein DL, Miller FG. Ethical considerations in psychopharmacological research involving decisionally impaired subjects. Psychopharmacology 2003; 171:92-97. The authors nicely explicate the concept of 'vulnerability' in the context of psychopharmacological research.
29. Frank E, Novick DM, Kupfer DJ. Beyond the question of placebo controls: ethical issues in psychopharmacological drug studies. Psychopharmacology 2003; 171:19-26.
30. Carpenter WT, Appelbaum PS, Levine RJ. The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry 2003; 160:356-362. Discusses the recent revision and subsequent clarification of the Declaration of Helsinki regarding placebo-controlled trials.
31. Michels R. Are research ethics bad for our mental health? New Engl J Med 1999; 340:1427-1430.
32. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363:2063-2072.
33. Capron AM. Ethical and human-rights issues in research on mental disorders that may affect decision-making capacity. N Engl J Med 1999; 340:1430-1434.
34. Pinals DA, Appelbaum PS. The history and current status of competence and informed consent in psychiatric research. Isr J Psychiatry Relat Sci 2000; 37:82-94.
35. Carpenter WT, Conley RR. Sense and nonsense: an essay on schizophrenia research ethics. Schizophr Res 1999; 35:219-225.
36. Department of Health and Human Services. Protection of human subjects. Code of Federal Regulations, Title 45, Public Welfare: Part 46; 1991.
37. Karlawish JH. Clinical value: the neglected axis in the system of research ethics. Account Res 1999; 7:255-264.
38. Michels R. Research on persons with impaired decision making and the public trust. Am J Psychiatry 2004; 161:777-779.
39. Stanley BH, Stanley M. Psychiatric patients in research: protecting their autonomy. Compr Psychiatry 1981; 22:420-427.
40. Pincus HA, Lieberman JA, Ferris S. Ethics in psychiatric research: a resource manual for human subjects protection. Washington, DC: American Psychiatric Association; 1999.
41. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report (DHEW Publ No OS-78-0012). Washington, DC: US Government Printing Office; 1978.
42. Committee on Assessing the System for Protecting Human Research Participants, Institute of Medicine. Responsible research: a systems approach to protecting research participants, Federman DD, Hanna KE, Lyman Rodriguez L, editors. Washington, DC: National Academies Press; 2002.
43. Levine RJ. Clinical trials and physicians as double agents. Yale J Biol Med 1992; 65:65-74.
44. Rennie D, Yank V, Emanuel L. When authorship fails: a proposal to make contributors accountable. JAMA 1997; 278:579-585.
45. Appelbaum PS, Roth LH. Competency to consent to research: a psychiatric overview. Arch Gen Psychiatry 1982; 39:951-958.
46. Appelbaum PS, Grisso T. The MacArthur treatment competence study. I: Mental illness and competence to consent to treatment. Law Hum Behav 1995; 19:105-126.
47. Stanley B, Stanley M, Lautin A, et al. Preliminary findings on psychiatric patients as research participants: a population at risk? Am J Psychiatry 1981; 138:669-671.
48. Grossman L, Summers F. A study of the capacity of schizophrenic patients to give informed consent. Hosp Commun Psychiatry 1980; 31:205-206.
49. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283:2701-2711.
50. Roberts LW. Ethical dimensions of psychiatric research: a constructive, criterion-based approach to protocol preparation. The Research Protocol Ethics Assessment Tool (RePEAT). Biol Psychiatry 1999; 46:1106-1119.
51. Roberts LW, Solomon Z, Roberts B, Keith SJ. Ethics in psychiatric research: resources for faculty development and resident education. Acad Psychiatry 1998; 22:1-20.
52. Rosenstein DL, Miller FG, Rubinow DR. A curriculum for teaching psychiatric research bioethics. Biol Psychiatry 2001; 50:802-808.
53. Beresin EV, Baldessarini RJ, Alpert J, Rosenbaum J. Teaching ethics of psychopharmacology research in psychiatric residency training programs. Psychopharmacology 2003; 171:105-111. Focusing on resident education regarding psychopharmacology research ethics, the authors recommend topics for inclusion.
54. Chen DT. Curricular approaches to research ethics training for psychiatric investigators. Psychopharmacology 2003; 171:112-119. Taking psychiatric investigators, including those in training, as the focus, the author describes and illustrates modules for teaching researchers about ethical issues pertaining to psychiatric research.
55. Roberts LW, Warner TD, Brody JL, et al. What is ethically important in clinical research? A preliminary study of attitudes of 73 psychiatric faculty and residents. Schizophrenia Bull 2003; 29:607-613. In this survey study, the authors found that both psychiatric faculty and residents rated investigator integrity as the most important element in conduct of human research. Of factors that emerged from the responses, safeguards and scientific merit represented the most relevant for both residents and faculty.
56. Department of Health and Human Services, Office of Inspector General, Recruiting Human Subjects. Pressures in industry-sponsored clinical research. OEI-01-97-00195; June 2000.
57. Kim SY, Millard RW, Nisbet P, et al. Potential research participants' views regarding researcher and institutional financial conflicts of interest. J Med Ethics 2004; 30:73-79. The authors used an elegant Internet-based survey to ascertain potential research participants' (with a diagnosis of depression, breast cancer, or coronary heart disease) views of conflict of interest information for research. The large majority wanted to know about financial conflicts as part of informed consent.
58. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190:583-592.
59. Warner TD, Gluck JP. What do we really know about conflicts of interest in biomedical research? Psychopharmacology 2003; 171:36-46. The authors reviewed empirical studies on conflicts of interest in biomedical research, concluding that much more research is needed before we can have a meaningful understanding of the extent and nature of potential and real conflicts of interest.
60. Carpenter W. The schizophrenia ketamine challenge study debate. Biol Psychiatry 1999; 46:1081-1091.
61. D'Souza DC, Berman RM, Krystal JH, Charney DS. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry 1999; 46:1060-1080.
62. Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed consent in early psychosis research: National Institute of Mental Health Workshop, November 15, 2000. Schizophr Bull 2001; 27:571-583.
63. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51:31-38.
64. Fleischhacker WW, Czobor P, Hummer M, et al. Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 2003; 60:458-464. Argued that scientific and ethical concerns support increased use of noninferiority trials rather than placebo controlled trials of new drugs for the treatment of schizophrenia.
65. Kim SYH. Benefits and burdens of placebos in psychiatric research. Psychopharmacology 2003; 171:13-18. Outlined arguments for and against use of placebos in psychiatric research, noting the absence of long-term data on effects of placebo use by participants in antidepressant and antipsychotic clinical trials. Emphasized the importance of further empirical study of the ethically relevant dimensions of placebo use.
66. Weijer C. Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?. Schizophr Res 1999; 35:211-218.
67. Roberts LW, Warner TD, Brody JL, et al. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry 2002; 159:573-584.
68. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry 2001; 158:1449-1454.
69. Storosum JG, van Zwieten BJ, Wohlfarth T, et al. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry 2003; 60:365-368. Reviewed 10 years of placebo-controlled antipsychotic trials in the Netherlands; no significant differences in suicidal behavior (attempts or completed suicides) between patients taking placebo and those taking active drugs.
70. Biesecker BB, Peay HL. Ethical issues in psychiatric genetics research: points to consider. Psychopharmacology 2003; 171:27-35. Review of important issues in psychiatric genetics research, focusing on the need for investigators to consider proactively the kinds of concerns that will arise when susceptibility information may be offered to research subjects.
71. Roberts LW, Warner TD, Geppert CMA, et al. Employees' perspectives on ethically important aspects of genetic research participation: a pilot study. Compr Psychiatry 2005; 46:27-33.
72. Karlawish JH, Lantos J. Community equipoise and the architecture of clinical research. Camb Q Healthc Ethics 1997; 6:385-396.
73. Jeste DV, Dunn LB, Palmer BW, et al. A collaborative model for research on decisional capacity and informed consent in older patients with schizophrenia: bioethics unit of a geriatric psychiatry intervention research center. Psychopharmacology 2003; 171:68-74. Describes the initial formation and subsequent role of a bioethics unit in a research center focused on older people with psychoses.
74. Osborn DP, Fulford KW. Psychiatric research: what ethical concerns do LRECs encounter? A postal survey. Local research ethics committees. J Med Ethics 2003; 29:55-56. Survey of local research ethics councils in the UK; highlights some common areas of concern that these review boards encounter.
75. Sugarman J, Eckenwiler LA, Emanuel EJ. Research oversight through new lenses: the Consortium to Examine Clinical Research Ethics. IRB 2003; 25:9-10.
76. Roberts LW, Warner TD, Anderson CT, et al. Schizophrenia research participants' responses to protocol safeguards: recruitment, consent, and debriefing. Schizophr Res 2004; 67:283-291. Interviewed 28 individuals with schizophrenia who had participated in a research protocol; volunteers provided their views on various aspects of the research experience. An example of the usefulness of conducting qualitative research to gather stakeholder views on important, ethically related issues in schizophrenia research.
77. Roberts LW, Hammond KA, Warner TD, Lewis R. Influence of ethical safeguards on research participation: comparison of perspectives of people with schizophrenia and psychiatrists. Am J Psychiatry 2004; 161:2309-2311. Key research safeguards (informed consent, IRB review, data safety monitoring boards, confidentiality measures, and alternative decision-makers) were viewed as protective by both psychiatrists and people with schizophrenia.
78. Roberts LW, Roberts B. Psychiatric research ethics: an overview of evolving guidelines and current ethical dilemmas in the study of mental illness. Biol Psychiatry 1999; 46:1025-1038.
79. Jaskiw GE, Blumer TE, Gutierrez-Esteinou R, et al. Comparison of inpatients with major mental illness who do and do not consent to low-risk research. Psychiatry Res 2003; 119:183-188. Compared patients who did and did not agree to participate in a low-risk research study. Those who agreed were younger and were more likely to have a diagnosis of schizophrenia.
80. Roberts LW, Warner TD, Brody JL. Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry 2000; 157:67-74.
81. Kaminsky A, Roberts LW, Brody JL. Influences upon willingness to participate in schizophrenia research: an analysis of narrative data from 63 people with schizophrenia. Ethics Behav 2003; 13:279-302. Summarizes interview data from patients with schizophrenia regarding attitudes and beliefs regarding schizophrenia research. Interviews were analyzed to assess for differential pattern of responses between those who had participated in a clinical protocol versus those who had not.
82. Verheggen FW, Nieman F, Jonkers R. Determinants of patient participation in clinical studies requiring informed consent: why patients enter a clinical trial. Patient Educ Couns 1998; 35:111-125.
83. Mattson ME, Curb JD, McArdle R. Participation in a clinical trial: the patients' point of view. Control Clin Trials 1985; 6:156-167.
84. Warner TD, Roberts LW, Nguyen K. Do psychiatrists understand research-related experiences, attitudes, and motivations of schizophrenia study participants? Compr Psychiatry 2003; 44:227-233. Described psychiatrists' and patients' views regarding research participation; psychiatrists generally were accurate at predicting patients' attitudes but under-estimated the positive aspects of the patients' experience as well as the patients' altruistic motives.
85. Hummer M, Holzmeister R, Kemmler G, et al. Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry 2003; 64:277-281. Surveyed 100 inpatients with schizophrenia regarding attitudes toward participation in placebo-controlled clinical trials. Fifty-six percent of the patients reported being unwilling to participate, mainly because of concerns about side effects. The majority were in favor of clinical trials in general.
86. Roberts LW, Geppert C, Warner TD, et al. Perspectives on use and protection of genetic information in work settings: results of a preliminary study. Soc Sci Med 2004 (in press).
87. Roberts LW, Warner TD, Nguyen KP, et al. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology 2003; 171:58-67. Using as a stimulus a hypothetical protocol in which a volunteer experienced emergence of severe symptoms during a washout phase, the authors found that psychiatrists underestimated schizophrenia patients' assessments of the risk of the protocol. Patients expressed low willingness to participate in the hypothetical protocol.
88. Saks ER, Jeste DV, Granholm E, et al. Ethical issues in psychosocial interventions research involving controls. Ethics Behav 2002; 12:87-101.
89. Carpenter WT Jr, Gold JM, Lahti AC, et al. Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry 2000; 57:533-538.
90. Dunn LB, Jeste DV. Enhancing informed consent for research and treatment. Neuropsychopharmacology 2001; 24:595-607.
91. Oldham JM, Haimowitz S, Delano SJ. Protection of persons with mental disorders from research risk: a response to the report of the National Bioethics Advisory Commission. Arch Gen Psychiatry 1999; 56: 688-693.
92. Grisso T, Appelbaum PS, Mulvey EP, Fletcher K. The MacArthur Treatment Competence Study. II: Measures of abilities related to competence to consent to treatment. Law Hum Behav 1995; 19:127-148.
93. Grisso T, Appelbaum PS. The MacArthur Treatment Competence Study. III: Abilities of patients to consent to psychiatric and medical treatments. Law Hum Behav 1995; 19:149-174.
94. Grisso T, Appelbaum PS, Hill-Fotouhi C. The MacCAT-T: a clinical tool to assess patients' capacities to make treatment decisions. Psychiatr Serv 1997; 48:1415-1419.
95. Grisso T, Appelbaum PS. Assessing competence to consent to treatment: a guide for physicians and other health professionals. New York: Oxford University Press; 1998.
96. Appelbaum PS, Grisso T. MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research. Sarasota, FL: Professional Resource Press; 2001
97. Grisso T. Evaluating competencies: forensic assessments and instruments. 2nd ed. New York: Kluwer Academic/Plenum Publishers; 2003. A very useful reference for understanding the background, construction, and use of numerous assessment tools including competence assessment tools.
98. Moser DJ, Schultz SK, Arndt S, et al. Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry 2002; 159:1201-1207.
99. Kovnick JA, Appelbaum PS, Hoge SK, Leadbetter RA. Competence to consent to research among long-stay inpatients with chronic schizophrenia. Psychiatr Serv 2003; 54:1247-1252. Using MacCAT-CR, assessed decision-making capacity among hospitalized patients with schizophrenia compared with healthy controls; the patients showed variation in performance but performed worse than the controls on measures of understanding, appreciation, and reasoning. In this study, psychopathology and cognitive functioning were both negatively associated with capacity scores in the patient group.
100. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997; 11:437-446.
101. Green MF. Schizophrenia from a neurocognitive perspective: probing the impenetrable darkness. Boston, MA: Allyn and Bacon; 1998.
102. Wirshing DA, Wirshing WC, Marder SR, et al. Informed consent: assessment of comprehension. Am J Psychiatry 1998; 155:1508-1511.
103. Palmer BW, Dunn LB, Appelbaum PS, Jeste DV. Correlates of treatment-related decision-making capacity among middle-aged and older patients with schizophrenia. Arch Gen Psychiatry 2004; 61:230-236. Among middle-aged and older patients with schizophrenia, the authors found heterogeneity of performance on the MacCAT-T (assessing treatment-related decision-making regarding use of antipsychotic medications). Cognitive performance, more so than severity of psychopathology, was correlated with performance on the MacCAT-T.
104. Miller FG. Ethical significance of ethics-related empirical research. J Natl Cancer Inst 2002; 94:1821-1822.
105. Miller FG. Research ethics and misguided moral intuition. J Law Med Ethics 2004; 32:111-116.
106. Department of Health and Human Services, National Institutes of Health, Office of Protection from Research Risks. Code of Federal Regulations, Title 45: Public Welfare. Part 46: Protection of Human Subjects; 1991.
107. Dunn LB, Jeste DV. Problem areas in the understanding of informed consent for research: study of middle-aged and older patients with psychotic disorders. Psychopharmacology 2003; 171:81-85. Problem areas (areas on which patients had more difficulty answering short-answer items correctly) involved the risks of the research, the procedures, and the time involved. Open-ended questions were more difficult than simple yes/no questions.
108. Roberts LW. Informed consent and the capacity for voluntarism. Am J Psychiatry 2002; 159:705-712.
109. Appelbaum PS, Roth LH, Lidz C. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 1982; 5:319-329.
110. Lidz CW, Appelbaum PS. The therapeutic misconception; problems and solutions. Med Care 2002; 40:V55-V63.
111. Advisory Committee on Human Radiation Experiments. Final report. Washington, DC: GPO; 1995.
112. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase 1 trials. J Clin Oncol 1995; 13:1062-1072.
113. Rodenhuis S, van den Heuvel WJ, Annyas AA, et al. Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol 1984; 20:457-462.
114. Penman DT, Holland JC, Bahna GF, et al. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol 1984; 2:849-855.
115. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, et al. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med 1991; 32:35-42.
116. Weinfurt KP, Castel LD, Li Y, Sulmasy DP, et al. The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 2003; 98:166-175.
117. Lidz CW, Appelbaum PS, Grisso T, Renaud M. Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med 2004; 58:1689-1697. Extensively interviewed 225 individuals enrolling in 44 varied research studies (medical and psychiatric). Over 60% of participants manifested a therapeutic misconception based on one or both definitions: inaccurate beliefs about individualization of treatment (TMV) or unreasonable beliefs about the nature or likelihood of benefit ('TM2').
118. Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB 2004; 26:1-8. Extensively interviewed 225 individuals enrolling in 44 varied research studies (medical and psychiatric). Over 60% of participants manifested a therapeutic misconception based on one or both definitions: inaccurate beliefs about individualization of treatment ('TM1') or unreasonable beliefs about the nature or likelihood of benefit ('TM2').
119. Nelson RM, Merz JF. Voluntariness of consent for research: an empirical and conceptual review. Med Care 2002; 40(9 Suppl):V69-V80.
120. Stiles PG, Poythress NG, Hall A, et al. Improving understanding of research consent disclosures among persons with mental illness. Psychiatr Serv 2001; 52:780-785.
121. Dunn LB, Lindamer LA, Palmer BW, et al. Improving understanding of research consent in middle-aged and elderly patients with psychotic disorders. Am J Geriatr Psychiatry 2002; 10:142-150.
122. Agre P, Campbell FA, Goldman BD, et al. Improving informed consent: the medium is not the message. IRB 2003; 25(Suppl 25):S11-S19. Describes research on methods to improve informed consent. The study by Mintz and colleagues found a positive effect of an informational video designed to stimulate more involvement in decision-making by the potential participants.